Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849404 | 0.80 | HPGD (0.41) | MAPTLMNAMAOAMAOBMEN1 | |
| SCHEMBL435023 | 0.79 | DDB1 (0.48) | METAP1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL18500494 | 0.77 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL12038178 | 0.76 | MEN1 (0.54) | ACHEHTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL10196873 | 0.72 | PARP1 (0.45) | METAP1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL10177046 | 0.71 | MAOA (0.36) | METAP1PARP10MAPTLMNAMAOA | |
| SCHEMBL5984538 | 0.69 | METAP1 (0.42) | METAP1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL8343209 | 0.69 | METAP1 (0.50) | METAP1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL435022 | 0.68 | METAP1 (0.44) | METAP1HTR2AHTR2CHTR2BPARP10 | |
| SCHEMBL5985200 | 0.68 | MAPT (0.45) | METAP1ACHEHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-8324200-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885ACHE 4826/4885HTR2A 3683/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | METAP1 3367/4885ACHE 4826/4885HTR2A 3683/4885 |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885ACHE 4826/4885HTR2A 3683/4885 |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3367/4885ACHE 4826/4885HTR2A 3683/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | METAP1 3500/4885ACHE 4878/4885HTR2A 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.